A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (NCT07450859)
A Phase 2 Study of BT5528 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 2 study for nuzefatide pevedotin (BT5528) in adults with a specific type of pancreatic cancer called metastatic pancreatic ductal adenocarcinoma (PDAC) that has spread and worsened after one previous treatment or two prior lines of treatment if treated with KRAS inhibitor. The drug, nuzefatide pevedotin (nuzefatide), is designed to find a specific protein called EphA2. The main aims of the study are to see how well the drug works against the tumor (efficacy), what side effects it may have (safety), and how the body processes it (pharmacokinetics). All participants in this study will receive nuzefatide, and both they and their doctors will know what is being administered (single-arm, open-label). The trial will take place at several different medical centers.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic Arizona — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (6 Sites)
- Mayo Clinic Arizona — Phoenix, Arizona
- Mayo Clinic Florida — Jacksonville, Florida
- Mayo Clinic Rochester — Rochester, Minnesota
- Siteman Cancer Center (Washington University School of Medicine) — St Louis, Missouri
- Memorial Sloan Kettering Cancer Center - Main Campus — New York, New York
- Thomas Jefferson University, Sidney Kimmel Comprensive Cancer Center, Clinical Trials Office — Philadelphia, Pennsylvania
📞 Contact the Study Coordinator
Phone: (617) 945-8155
Email: clinicalstudies@bicycletx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Pancreatic Ductal Adenocarcinoma (PDAC)
- Reach and Engagement of GENetic Education, Risk Assessment, and TEsting Feasibility Trial — Boston, Massachusetts
- Using Strength Tests to Better Understand How Pancreatic Cancer Affects Muscle Mass and Quality of Life — Vancouver, British Columbia
- PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP) — Burlington, Vermont
- ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC) — Birmingham, Alabama
- Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer — La Jolla, California
- A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer — Los Angeles, California
Explore by condition: All Pancreatic Ductal Adenocarcinoma (PDAC) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.